Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
Express Scripts
Merck
McKesson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208944

See Plans and Pricing

« Back to Dashboard

NDA 208944 describes GOCOVRI, which is a drug marketed by Adamas Pharma and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GOCOVRI profile page.

The generic ingredient in GOCOVRI is amantadine hydrochloride. There are seven drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.
Summary for 208944
Tradename:GOCOVRI
Applicant:Adamas Pharma
Ingredient:amantadine hydrochloride
Patents:14
Formulation / Manufacturing:see details
Pharmacology for NDA: 208944
Mechanism of ActionM2 Protein Inhibitors
Medical Subject Heading (MeSH) Categories for 208944
Suppliers and Packaging for NDA: 208944
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944 NDA Adamas Pharma, LLC 70482-085 70482-085-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (70482-085-60)
GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944 NDA Adamas Pharma, LLC 70482-170 70482-170-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (70482-170-60)
Paragraph IV (Patent) Challenges for 208944
Tradename Dosage Ingredient NDA Submissiondate
GOCOVRI CAPSULE, EXTENDED RELEASE;ORAL amantadine hydrochloride 208944 2018-01-16

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 68.5MG BASE
Approval Date:Aug 24, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 24, 2024
Regulatory Exclusivity Use:TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
Regulatory Exclusivity Expiration:Aug 24, 2020
Regulatory Exclusivity Use:TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
Patent:  Start TrialPatent Expiration:Dec 4, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Mallinckrodt
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.